Scleritis: A paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease

Journal of Rheumatology

Volumn 39, Issue 2, 2012, Pages 233-239

  Gaujoux Viala, Cécile ^a,b   Giampietro, Cecilia ^a,b   Gaujoux, Thomas ^c,d   Ea, Hang Korng ^c,e   Prati, Clément ^f   Orcel, Philippe ^c,e   Wendling, Daniel ^f   Lioté, Frédéric ^c,e  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Etanercept; Rheumatoid arthritis; Scleritis

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INDOMETACIN; INFLIXIMAB; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; CASE REPORT; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; IRIDOCYCLITIS; MALE; PRIORITY JOURNAL; RELAPSE; REMISSION; RHEUMATOID ARTHRITIS; SCLERITIS; SJOEGREN SYNDROME; SKIN NODULE; SYSTEMIC THERAPY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; SCLERITIS; TREATMENT OUTCOME;

EID: 84856542193     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110865     Document Type: Article

References (30)

1. Le Garrec J, Marcelli C, Mouriaux F. [Can tumor necrosis factor inhibitors induce sclero-uveitis?]. French. J Fr Ophtalmol 2009;32:511.e1-6.
2. Hamideh F, Prete PE. Ophthalmologic manifestations of rheumatic diseases. Semin Arthritis Rheum 2001;30:217-41. (Pubitemid 32172728)
3. Smith JR, Macksen F, Rosenbaum JT. Therapy insight: Scleritis and its relationships of systemic autoimmune disease. Nat Clin Pract Rheumatol 2007;3:219-26. (Pubitemid 46860406)
4. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNF-alpha agents. J Pediatr 2006;149:833-6. (Pubitemid 44816346)
5. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-50. (Pubitemid 46580481)
6. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51. (Pubitemid 41117431)
7. Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: A retrospective study. Ann Rheum Dis 2006;65:1631-4. (Pubitemid 44799677)
8. Cobo-Ibanez T, del Carmen Ordonez M, Munoz-Fernandez S, Madero-Prado R, Martin-Mola E. Do TNF-blockers reduce or induce uveitis? Rheumatology 2008;47:731-2. (Pubitemid 351619221)
9. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317-23. (Pubitemid 44838928)
10. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-52. (Pubitemid 47585419)
11. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252-7. (Pubitemid 32952905)
12. Restrepo JP, Molina MP. Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol 2010;29:559-61.
13. Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 2000;43:243-9.
14. Taban M, Dupps WJ, Mandell B, Perez VL. Etanercept (Enbrel)-associated inflammatory eye disease: Case report and review of the literature. Ocul Immunol Inflamm 2006;14:145-50. (Pubitemid 43890770)
15. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol 2003;87:925.
16. Coates LC, McGonagle DG, Bennett AN, Emery P, Marzo-Ortega H. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. Ann Rheum Dis 2008;67:729-30. (Pubitemid 351571948)
17. Sugita S, Takase H, Taguchi C, Mochizuki M. The role of soluble TNF receptors for TNF-alpha in uveitis. Invest Ophthalmol Vis Sci 2007;48:3246-52. (Pubitemid 351261170)
18. Kollias G, Douni E, Kassiotis G, Kontoyiannis D. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 1999;58 Suppl 1:I32-9.
19. Smith JR, Hart PH, Coster DJ, Williams KA. Mice deficient in tumor necrosis factor receptors p55 and p75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1998;39:658-61. (Pubitemid 28110703)
20. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology 2005;44:1008-11. (Pubitemid 41487173)
21. Kaipiainen-Seppanen O, Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2003;62:88-9. (Pubitemid 36005808)
22. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101. (Pubitemid 36418252)
23. Tiliakos AN, Tiliakos NA. Ocular inflammatory disease in patients with RA taking etanercept: Is discontinuation of etanercept necessary? J Rheumatol 2003;30:2727. (Pubitemid 37549362)
24. Monnet D, Moachon L, Dougados M, Brezin AP. Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis. Nat Clin Pract Rheumatol 2006;2:393-7.
25. Botsios C, Sfriso P, Ostuni PA, Todesco S, Punzi L. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases. Rheumatology 2007;46:1042-3. (Pubitemid 47062524)
26. Caramaschi P, Biasi D, Carletto A, Bambara LM. Orbital myositis in a rheumatoid arthritis patient during etanercept treatment. Clin Exp Rheumatol 2003;21:136-7. (Pubitemid 36267548)
27. Scrivo R, Spadaro A, Spinelli FR, Valesini G. Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. Arthritis Rheum 2008;58:1555-6; author reply 1556-7.
28. Wang F, Wang NS. Etanercept therapy-associated acute uveitis: A case report and literature review. Clin Exp Rheumatol 2009;27:838-9.
29. Fouache D, Goëb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: A retrospective study. Rheumatology 2009;48:761-4.
30. Martín-Mola E, Sieper J, Leirisalo-Repo M, Dijkmans BA, Vlahos B, Pedersen R, et al. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010;28:238-45.